BioCare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization)

BroadOak partnered with United BioChannels (UBC) to acquire ORFLO Technologies (ORFLO) in October 2022. ORFLO, a

Flagship Biosciences hired industry veteran Tom Turi as Chief Scientific Officer. Tom will help grow the

BroadOak completed a growth equity investment in EmVenio Research, alongside members of the company’s management team

Following BroadOak’s growth equity investment in Flagship Biosciences, Flagship Biosciences has acquired Interpace Pharma Solutions, a

BroadOak joined Agilent Technologies, a global leader in life sciences and diagnostics, to increase its investment

BroadOak invested in Microsize, a CDMO specializing in micronization and particle size control, as part of

BroadOak invested in Kemp Proteins, a leading CDMO specializing in the production of novel proteins. The

BroadOak Capital Partners advised Bioresource Technology (“BRT”) on the sale of the company to Medix Biochemica.